Sign in
Not yet recruitingPhase 3

Impact on delirium of the use of DEXmedetomidine as first-line sedation in PEDIAtric intensive care: the PEDIADEX randomized controlled trial

Key facts

Who runs it
Centre Hospitalier Regional Universitaire De Tours
Where
France7 sites in 1 countryChoose a country to see its sites
Status
Not yet recruiting
Phase
Phase 3
People taking part
266 people, planned
Started
23 Feb 2026
Expected to end
23 May 2029
Type of study
Interventional
Record updated
29 October 2025

Who can take part

Age
Up to 17 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Children between 1 month to 17 years and 6 months
  • Participants covered by or entitled to French social security
  • Informed consent, dated and signed, from the participant's legal representative(s). (The emergency inclusion procedure will be used if the legal representative(s) cannot be contacted. When the legal representative(s) and the patient are available and/or able to consent, informed consent from the participant’s legal representative(s)
  • Ability for participant to comply with the requirements of the study
  • Receiving sedation by benzodiazepines for less than 6 hours at the time of inclusion

Who cannot take part

  • Patient already enrolled in the study previously
  • Need for paralytic medication (neuromuscular blocker) at admission to PICU
  • High-grade heart conduction disorder (Second or third-degree atrioventricular block)
  • Intracranial hypertension
  • Following cardiac surgery
  • Pregnant or breastfeeding woman (positive pregnancy test for women of childbearing age)
  • Patients under guardianship, curatorship or legal protection
  • Palliative care on admission
  • Significant bradycardia (cf table)
  • Severe hepatic dysfunction (CHILD score C or worse) due to the hepatic metabolism of dexmedetomidine
  • Expected duration of invasive mechanical ventilation inferior to 12 hours
  • Hospitalized in a pediatric intensive care unit without computerized prescription software
  • Study interventions contraindications
  • Status epilepticus
  • Sedation for more than 6 hours by benzodiazepines at the time of inclusion

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To assess if continuous intravenous infusion of dexmedetomidine is effective to reduce the prevalence of delirium in critically ill children, needing mechanical ventilation for more than 12 hours.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
29 October 2025